This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock TENK vs. ATOS, HURA, PROC, TNYA, HLVX, CTNM, MCRB, ANIX, SAVA, and COYAShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), Tenaya Therapeutics (TNYA), HilleVax (HLVX), Contineum Therapeutics (CTNM), Seres Therapeutics (MCRB), Anixa Biosciences (ANIX), Cassava Sciences (SAVA), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Its Competitors Atossa Genetics TuHURA Biosciences Procaps Group Tenaya Therapeutics HilleVax Contineum Therapeutics Seres Therapeutics Anixa Biosciences Cassava Sciences Coya Therapeutics TenX Keane Acquisition (NASDAQ:TENK) and Atossa Genetics (NASDAQ:ATOS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends. Does the media refer more to TENK or ATOS? In the previous week, Atossa Genetics had 1 more articles in the media than TenX Keane Acquisition. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for TenX Keane Acquisition. Atossa Genetics' average media sentiment score of 1.89 beat TenX Keane Acquisition's score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Overall Sentiment TenX Keane Acquisition Neutral Atossa Genetics Very Positive Which has better earnings & valuation, TENK or ATOS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenX Keane AcquisitionN/AN/AN/AN/AN/AAtossa GeneticsN/AN/A-$25.50M-$0.21-4.21 Do insiders and institutionals hold more shares of TENK or ATOS? 70.5% of TenX Keane Acquisition shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 22.9% of TenX Keane Acquisition shares are held by company insiders. Comparatively, 7.6% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer TENK or ATOS? Atossa Genetics has a consensus price target of $6.17, suggesting a potential upside of 597.59%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Atossa Genetics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is TENK or ATOS more profitable? TenX Keane Acquisition's return on equity of 0.00% beat Atossa Genetics' return on equity.Company Net Margins Return on Equity Return on Assets TenX Keane AcquisitionN/A N/A N/A Atossa Genetics N/A -33.90%-31.53% SummaryAtossa Genetics beats TenX Keane Acquisition on 6 of the 10 factors compared between the two stocks. Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ ExchangeMarket Cap$10.45M$208.01M$2.03B$9.40BDividend YieldN/A3.15%13.72%4.09%P/E RatioN/A1.8812.3319.86Price / SalesN/A547.872,533,931.5198.68Price / CashN/A109.2857.5157.53Price / BookN/A8.783.215.71Net IncomeN/A-$10.64M-$461.08M$257.80M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$1.57+1.9%N/A-86.5%$10.45MN/A0.00N/AGap DownHigh Trading VolumeATOSAtossa Genetics3.1569 of 5 stars$0.90+6.2%$6.17+585.2%-36.3%$109.43MN/A-4.298Positive NewsHURATuHURA Biosciences1.5172 of 5 stars$2.49+0.4%$12.67+408.7%N/A$108.33MN/A0.00N/APROCProcaps GroupN/A$0.95-40.3%N/A-62.2%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeTNYATenaya Therapeutics3.4988 of 5 stars$0.67+6.1%$6.25+831.3%-81.0%$102.94MN/A-0.58110HLVXHilleVax2.0832 of 5 stars$2.12+3.4%$2.00-5.7%+15.8%$102.79MN/A-0.9920Positive NewsCTNMContineum Therapeutics3.6817 of 5 stars$4.01+2.3%$22.50+461.1%-82.4%$101.42M$50M-2.0431High Trading VolumeMCRBSeres Therapeutics3.4616 of 5 stars$12.38+6.7%$73.67+495.0%-45.0%$101.30M$126.32M-2.69330Positive NewsANIXAnixa Biosciences2.9644 of 5 stars$3.15+0.3%$9.00+185.7%+4.3%$101.14M$210K-8.295SAVACassava Sciences4.1614 of 5 stars$2.19+5.3%$54.50+2,388.6%-84.7%$100.48MN/A-1.4630Positive NewsCOYACoya Therapeutics1.7854 of 5 stars$6.22+3.7%$16.50+165.3%-24.5%$100.35M$3.55M-5.816Gap Up Related Companies and Tools Related Companies ATOS Alternatives HURA Alternatives PROC Alternatives TNYA Alternatives HLVX Alternatives CTNM Alternatives MCRB Alternatives ANIX Alternatives SAVA Alternatives COYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENK) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
